Lv1
40 积分 2025-08-22 加入
Cost-effectiveness analysis of the first‐line EGFR‐TKIs in patients with advanced EGFR-mutated non-small-cell lung cancer
3天前
已完结
Sacituzumab Tirumotecan in EGFR-TKI–Resistant, EGFR -Mutated Advanced NSCLC
12天前
已完结
The cost of Alzheimer's disease in China and re‐estimation of costs worldwide
18天前
已完结
Lecanemab in Early Alzheimer’s Disease
22天前
已完结
The efficacy and safety of memantine for the treatment of Alzheimer’s disease
23天前
已完结
Cost-Utility Of Afatinib And Gefitinib As First-Line Treatment For EGFR -Mutated Advanced Non-Small-Cell Lung Cancer
26天前
已完结
Cost-effectiveness analysis of the first‐line EGFR‐TKIs in patients with advanced EGFR-mutated non-small-cell lung cancer
27天前
已完结
Cost-effectiveness of lazertinib as first-line treatment in patients with EGFR-mutated advanced lung cancer
27天前
已完结
Sacituzumab Tirumotecan in EGFR-TKI–Resistant, EGFR -Mutated Advanced NSCLC
1个月前
已完结
Safety and short-term outcomes of lecanemab for Alzheimer's disease in China: a multicentre study
1个月前
已完结
皖公网安备34019202002308
